Neurotensin
(Synonyms: 神经降压素) 目录号 : GC16357
A neuropeptide with diverse biological activities
Cas No.:39379-15-2
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
IC50: N/A
Neurotensin (NT) can activate the G protein-coupled receptor, the neurotensin receptor 1 (NTR1). NT, a 13-amino acid neuropeptide, expressed in the central nervous system, and the intestine, including ileum3 and colon.
Neurotensin receptor 1 (NTR1) is a G protein-coupled receptor (neurotensin, NT) with high affinity.
In vitro: Due to NT/NTR1 signaling potentiates expression of miR-133α, the mechanism of NT-regulated miR-133α expression and examining the role of miR-133α in intracellular NTR1 trafficking in human NCM460 colonocytes are very important. The negative transcription regulator (zinc finger E-box binding homeobox 1) is involved in NT-induced miR-133α upregulation. A binding target of miR-133α (silencing of miR-133α or overexpression of aftiphilin (AFTPH)) lowered NTR1 trafficking to plasma membrane in human colonocytes without affecting NTR1 internalization. AFTPH to early endosomes and the trans-Golgi network (TGN) were localized in unstimulated human colonic epithelial cells. NTR1 localization was reduced by AFTPH overexpression in early endosomes. At the same time, it also increased expression of proteins related to endosomes and the TGN trafficking pathway. NTR1 expression was increased by AFTPH overexpression and de-acidification of intracellular vesicles. These results suggest a novel mechanism of GPCR trafficking in human colonic epithelial cells accounts for why a microRNA, miR-133α regulates NTR1 trafficking through its downstream target AFTPH.
In vivo: So far, no study in vivo has been conducted.
Clinical trial: So far, no clinical study has been conducted.
Reference:
[1]. Law IK, Jensen D, Bunnett NW, Pothoulakis C. Neurotensin-induced miR-133α expression regulates neurotensin receptor 1 recycling through its downstream target aftiphilin. Sci Rep. 2016 Feb 23;6:22195.
| Cas No. | 39379-15-2 | SDF | |
| 别名 | 神经降压素 | ||
| 化学名 | (Z)-5-(((Z)-1-((6-amino-1-(2-((Z)-(((Z)-1-((1-(2-((Z)-(((Z)-1-(((Z)-1-((1-carboxy-3-methylbutyl)imino)-1-hydroxy-3-methylpentan-2-yl)imino)-1-hydroxy-3-(4-hydroxyphenyl)propan-2-yl)imino)(hydroxy)methyl)pyrrolidin-1-yl)-5-guanidino-1-oxopentan-2-yl)imino) | ||
| Canonical SMILES | CCC(C(/N=C(O)/C(/N=C(O)/C1CCCN1C(C(/N=C(O)/C(/N=C(O)/C2CCCN2C(C(/N=C(O)/C(/N=C(O)/C(/N=C(O)/C(/N=C(O)/C(/N=C(O)/C3CCC(O)=N3)CC(C)C)CC4=CC=C(O)C=C4)CCC(O)=O)CC(O)=N)CCCCN)=O)CCCNC(N)=N)CCCNC(N)=N)=O)CC5=CC=C(O)C=C5)/C(O)=N/C(C(O)=O)CC(C)C)C | ||
| 分子式 | C78H121N21O20 | 分子量 | 1672.94 |
| 溶解度 | Soluble to 0.70 mg/ml in sterile water | 储存条件 | Desiccate at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 0.5978 mL | 2.9888 mL | 5.9775 mL |
| 5 mM | 0.1196 mL | 0.5978 mL | 1.1955 mL |
| 10 mM | 0.0598 mL | 0.2989 mL | 0.5978 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。